CN1250651A - 一种预防和治疗颅内压增高的药物组合物 - Google Patents
一种预防和治疗颅内压增高的药物组合物 Download PDFInfo
- Publication number
- CN1250651A CN1250651A CN 98120141 CN98120141A CN1250651A CN 1250651 A CN1250651 A CN 1250651A CN 98120141 CN98120141 CN 98120141 CN 98120141 A CN98120141 A CN 98120141A CN 1250651 A CN1250651 A CN 1250651A
- Authority
- CN
- China
- Prior art keywords
- piracetam
- injection
- intracranial hypertension
- pharmaceutical composition
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010022773 Intracranial pressure increased Diseases 0.000 title claims abstract description 17
- 201000009941 intracranial hypertension Diseases 0.000 title claims abstract description 17
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229960004526 piracetam Drugs 0.000 claims abstract description 40
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000006 Nitroglycerin Substances 0.000 claims abstract description 15
- 229960003711 glyceryl trinitrate Drugs 0.000 claims abstract description 15
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940083618 sodium nitroprusside Drugs 0.000 claims abstract description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 10
- 229930195725 Mannitol Natural products 0.000 claims abstract description 10
- 235000010355 mannitol Nutrition 0.000 claims abstract description 10
- 239000000594 mannitol Substances 0.000 claims abstract description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 abstract description 16
- 208000001953 Hypotension Diseases 0.000 abstract description 13
- 230000036543 hypotension Effects 0.000 abstract description 13
- 230000002265 prevention Effects 0.000 abstract description 7
- 239000002337 osmotic diuretic agent Substances 0.000 abstract description 5
- 229940079172 Osmotic diuretic Drugs 0.000 abstract description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract description 2
- ZVHOSRMJDHCBSF-QWFKVUSTSA-M sodium;2-oxo-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-7-olate Chemical compound [Na+].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)[O-])=CC2=C1OC(=O)C=C2 ZVHOSRMJDHCBSF-QWFKVUSTSA-M 0.000 abstract 1
- 238000002347 injection Methods 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 15
- 238000007917 intracranial administration Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 239000007788 liquid Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000008215 water for injection Substances 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000010253 intravenous injection Methods 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011265 semifinished product Substances 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229940114655 nitroglycerin 10 mg Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98120141A CN1111405C (zh) | 1998-10-09 | 1998-10-09 | 吡拉西坦在制备预防和预防颅内压增高药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98120141A CN1111405C (zh) | 1998-10-09 | 1998-10-09 | 吡拉西坦在制备预防和预防颅内压增高药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1250651A true CN1250651A (zh) | 2000-04-19 |
CN1111405C CN1111405C (zh) | 2003-06-18 |
Family
ID=5226623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN98120141A Expired - Lifetime CN1111405C (zh) | 1998-10-09 | 1998-10-09 | 吡拉西坦在制备预防和预防颅内压增高药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1111405C (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102008430A (zh) * | 2010-12-17 | 2011-04-13 | 张家港市华菱化工机械有限公司 | 含吡乙酰胺的口服液 |
CN102657665A (zh) * | 2012-04-25 | 2012-09-12 | 和光学 | 复方脱水利尿药物组合物 |
CN103565814A (zh) * | 2012-08-09 | 2014-02-12 | 和光学 | 预防和治疗颅内压增高的药物组合物 |
CN104721183A (zh) * | 2015-04-09 | 2015-06-24 | 山东罗欣药业集团股份有限公司 | 一种含有吡拉西坦的药物组合物制剂及其制备方法 |
CN104814955A (zh) * | 2015-04-09 | 2015-08-05 | 山东罗欣药业集团股份有限公司 | 一种治疗脑水肿的药物组合物及其制剂 |
CN106074597A (zh) * | 2016-06-13 | 2016-11-09 | 中山大学 | 硝普钠作为吲哚胺2,3-双加氧酶-1抑制剂的用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5232700A (en) * | 1990-11-14 | 1993-08-03 | The Administrators Of The Tulane Educational Fund | Methods of prophylaxis and treatment of herpes simplex lesions utilizing piracetam as the active ingredient |
-
1998
- 1998-10-09 CN CN98120141A patent/CN1111405C/zh not_active Expired - Lifetime
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102008430A (zh) * | 2010-12-17 | 2011-04-13 | 张家港市华菱化工机械有限公司 | 含吡乙酰胺的口服液 |
CN102657665A (zh) * | 2012-04-25 | 2012-09-12 | 和光学 | 复方脱水利尿药物组合物 |
CN102657665B (zh) * | 2012-04-25 | 2013-09-11 | 和光学 | 复方脱水利尿药物组合物 |
CN103565814A (zh) * | 2012-08-09 | 2014-02-12 | 和光学 | 预防和治疗颅内压增高的药物组合物 |
CN103565814B (zh) * | 2012-08-09 | 2016-06-08 | 和光学 | 预防和治疗颅内压增高的药物组合物 |
CN104721183A (zh) * | 2015-04-09 | 2015-06-24 | 山东罗欣药业集团股份有限公司 | 一种含有吡拉西坦的药物组合物制剂及其制备方法 |
CN104814955A (zh) * | 2015-04-09 | 2015-08-05 | 山东罗欣药业集团股份有限公司 | 一种治疗脑水肿的药物组合物及其制剂 |
CN104721183B (zh) * | 2015-04-09 | 2017-10-03 | 山东罗欣药业集团股份有限公司 | 一种含有吡拉西坦的药物组合物制剂及其制备方法 |
CN104814955B (zh) * | 2015-04-09 | 2018-01-12 | 山东罗欣药业集团股份有限公司 | 一种治疗脑水肿的药物组合物及其制剂 |
CN106074597A (zh) * | 2016-06-13 | 2016-11-09 | 中山大学 | 硝普钠作为吲哚胺2,3-双加氧酶-1抑制剂的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN1111405C (zh) | 2003-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1091635A (zh) | 作为具有抗郁作用药物的2-氨基-6-正丙基-氨基-4,5,6,7-四氢苯并噻唑应用 | |
CN1105561A (zh) | 治疗酗酒不适的治疗组合物及其使用方法 | |
CN1111405C (zh) | 吡拉西坦在制备预防和预防颅内压增高药物中的应用 | |
CN1823768A (zh) | 西咪替丁冻干组合物 | |
CN1090175A (zh) | 促红细胞生成素抗贫血作用的增强剂 | |
CN1768760A (zh) | 一种含红花总黄酮药物组合物及其制备方法与用途 | |
CN1231223C (zh) | 灯盏花素输液制剂及其制备方法 | |
CN1481798A (zh) | 银杏达莫大容量注射液及制备方法 | |
CN1717232A (zh) | L-肉碱用于治疗心血管疾病的用途 | |
CN1712411A (zh) | 甘草酸和苦参素的复合盐及其制备方法和用途 | |
Stael von Holstein et al. | Tranexamic acid in gastric and duodenal bleeding | |
CN1827093A (zh) | 牛磺酸注射剂及制备方法 | |
CN1636581A (zh) | 一种红花药物组合物、其制备方法及其用途 | |
CN1919206A (zh) | 牡荆素注射剂及口服制剂 | |
CN1520859A (zh) | 治疗心脑血管病的丹红注射液 | |
CN1215844C (zh) | 加替沙星眼凝胶及其制备方法 | |
CN1415301A (zh) | 含有苦参素、前列腺素e1和阿司匹林的复方制剂及其制备方法和用途 | |
CN1136849C (zh) | 替硝唑胃漂浮缓释胶囊及其制备方法 | |
CN1616069A (zh) | 一种银杏药物组合物、其制备方法及其用途 | |
CN101167707B (zh) | 原儿茶醛的新用途 | |
CN1785172A (zh) | 丹参酮ⅱa磺酸钠输液及制备方法 | |
CN1768762A (zh) | 鹿茸精注射剂新的给药途径及其制备工艺、新适应症 | |
CN1593562A (zh) | 银杏叶提取物组合物 | |
CN1883468A (zh) | 一种含丹参酮ⅱa磺酸钠的药物组合物 | |
CN1650849A (zh) | 比索洛尔非肠道给药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Zhuhai Hefang Medicine Co., Ltd. Assignor: He Guangxue Contract record no.: 2010440000541 Denomination of invention: Application of Laci Staw in the preparation of drugs for preventing and treating intracranial hypertension Granted publication date: 20030618 License type: Exclusive License Open date: 20000419 Record date: 20100521 |
|
ASS | Succession or assignment of patent right |
Owner name: ZHUHAI HEFANG MEDICINE CO., LTD. Free format text: FORMER OWNER: HE GUANGXUE Effective date: 20140528 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100071 FENGTAI, BEIJING TO: 519000 ZHUHAI, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140528 Address after: 519000 Guangdong province Zhuhai city Xiangzhou district police Meihua Road West of Xiangzhou science and Technology Industrial Park Road No. 1, A building three floors Patentee after: Zhuhai Hefang Medicine Co., Ltd. Address before: 100071 Beijing City, Fengtai District City Road 5, Teikyo classic B room 1008 Patentee before: He Guangxue |
|
C56 | Change in the name or address of the patentee |
Owner name: ZHUHAI HEFAN MEDICINE CO., LTD. Free format text: FORMER NAME: ZHUHAI HEFANG MEDICINE CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 519000 Guangdong province Zhuhai city Xiangzhou district police Meihua Road West of Xiangzhou science and Technology Industrial Park Road No. 1, A building three floors Patentee after: Zhuhai and every medicine Limited by Share Ltd Address before: 519000 Guangdong province Zhuhai city Xiangzhou district police Meihua Road West of Xiangzhou science and Technology Industrial Park Road No. 1, A building three floors Patentee before: Zhuhai Hefang Medicine Co., Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 519000 Guangdong Province, Xiangzhou District People's road, No. 325, commercial building, Fu Chun, building 16 Patentee after: Zhuhai and every medicine Limited by Share Ltd Address before: 519000 Guangdong province Zhuhai city Xiangzhou district police Meihua Road West of Xiangzhou science and Technology Industrial Park Road No. 1, A building three floors Patentee before: Zhuhai and every medicine Limited by Share Ltd |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Zhuhai Hefang Medicine Co., Ltd. Assignor: He Guangxue Contract record no.: 2010440000541 Date of cancellation: 20170829 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20000419 Assignee: JIANGSU CHENPAI PHARMACEUTICAL CO.,LTD. Assignor: Zhuhai and every medicine Limited by Share Ltd Contract record no.: 2017500000012 Denomination of invention: Application of Laci Staw in the preparation of drugs for preventing and treating intracranial hypertension Granted publication date: 20030618 License type: Common License Record date: 20171110 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20030618 |